Recent Updates
Recently added Catalysts
MIRA Positive Sentiment

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy

Wednesday, June 17, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MIRA Pharmaceuticals has submitted a Phase 2a clinical trial protocol to the FDA for its investigational drug Ketamir-2, targeting chemotherapy-induced peripheral neuropathy. The study will be randomized, double-blind, and placebo-controlled, focusing on the safety, tolerability, and efficacy of oral Ketamir-2. This trial will take place at a leading cancer center in the U.S.
Price reaction · baseline $0.95 (2026-06-16 close) · hit pre-market · clean, no other MIRA news in the window
day 0 close · peak
+3%

Market Sentiment Analysis

POSITIVE FACTORS

  • MIRA Pharmaceuticals is advancing its clinical research.
  • The Phase 2a trial aims to address a significant medical need.
  • The study design includes a randomized, double-blind approach.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+5%
120-day peak, hindsight
Typical move
0.6%
average across 2 past catalysts
Cash runway
~21 mo
Low dilution risk

Full Press Release Details

Randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and dose-response efficacy of oral Ketamir-2 at a leading U.S. cancer center MIAMI, FL / ACCESS Newswire / June 17, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”) , a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the submission of a Phase 2a clinical trial protocol to the U.S. F…
You can read the full content here

Frequently Asked Questions

What is the purpose of the Phase 2a trial?

The trial aims to evaluate the safety, tolerability, and efficacy of Ketamir-2.

What type of study design is being used?

The study is randomized, double-blind, and placebo-controlled.

Where will the trial be conducted?

The trial will take place at a leading cancer center in the U.S.

What condition is Ketamir-2 targeting?

Ketamir-2 is targeting chemotherapy-induced peripheral neuropathy.

ShareAdd on Google
Tags: MIRA Viatris Investor Conferences Healthcare MIRA Pharmaceuticals Ketamir-2 chemotherapy-induced neuropathy Phase 2a trial FDA submission
Last updated: Jun 17, 2026

Biotech snapshot

Cash runway
$9M liquidity · $0M/mo burn
~21 mo
Low dilution risk

Catalyst track record

+5%
best trade around MIRA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MIRA.

See every catalyst's timing & PoA →